https://www.selleckchem.com/pr....oducts/pclx-001-ddd8
Local ablation of pancreatic cancer has been suggested as an option to manage locally advanced pancreatic cancer (LAPC) although no robust evidence has been published to date to support its application. The aim of this study is to compare overall survival (OS) and progression-free survival (PFS) in patients receiving both radiofrequency ablation (RFA) and conventional chemoradiotherapy (CHRT) with patients receiving CHRT only. This is a multicentre prospective randomized controlled trial (RCT). Patients with LAPC diagnosed by
Like
Comment
Share
